Skip to content
value.today

ADvantage Therapeutics, Inc.

Total raised
$19 M
2 rounds on record
Latest round
$14 M
Jun 2023
First round on record
Jun 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ADvantage Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2023$14 MNo. 2$10 to $50 million

ADvantage Therapeutics, Inc.: Raise no. 2, Jun 2023

Investors in this round

24 investors had bought by the notice of Jul 28, 2025: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $25 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$5,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Agustin Fernandez Santana III · Executive Officer, Director
  • David B. Buchsbaum · Executive Officer
  • Jeffrey B. Madden · Executive Officer, Director
  • Frank B. Mattner · Director
  • Walter B. Schmidt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Corporate Partners & Co. LLC (CRD 168356) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “Amounts include conversion of outstanding convertible securities.”

Signed by David Buchsbaum, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 28, 2025. Read the notice at the SEC.

equitySEC
Jun 2021$5 MNo. 1$2 to $10 million

ADvantage Therapeutics, Inc.: Raise no. 1, Jun 2021

Investors in this round

1 investor had bought by the notice of Jun 24, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Agustin Fernandez Santana III · Executive Officer, Director
  • Frank B. Mattner · Director
  • Jeffrey B. Madden · Director
  • Walter B. Schmidt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Agustin Fernandez Santana III, Executive Chairman. Source: SEC Form D, newest notice filed Jun 24, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ADvantage Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jul 2025

That is all the official record says: ADvantage Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of ADvantage Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 24 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ADvantage Therapeutics, Inc.
NameRoleNamed in
Agustin Fernandez Santana IIIExecutive officerJul 2025
David B. BuchsbaumExecutive officerJul 2025
Jeffrey B. MaddenExecutive officerJul 2025
Agustin Fernandez Santana IIIDirectorJul 2025
Frank B. MattnerDirectorJul 2025
Jeffrey B. MaddenDirectorJul 2025
Walter B. SchmidtDirectorJul 2025
James B. O'NeillDirectorJul 2023